BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20947267)

  • 1. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
    Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
    Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
    Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study.
    Carraro S; Roca EL; Cartelli C; Rafailovici L; Castillo Odena S; Wasserman E; Gualdrini U; Huertas E; Barugel M; Ballarino G; Rodriguez MC; Masciangioli G
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):397-402. PubMed ID: 12243813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
    Rosenthal DI; Catalano PJ; Haller DG; Landry JC; Sigurdson ER; Spitz FR; Benson AB
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):108-13. PubMed ID: 18722265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
    Liang JT; Lai HS; Cheng KW
    Surg Endosc; 2011 Jan; 25(1):305-8. PubMed ID: 20526625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
    Gérard JP; Chapet O; Nemoz C; Romestaing P; Mornex F; Coquard R; Barbet N; Atlan D; Adeleine P; Freyer G
    J Clin Oncol; 2003 Mar; 21(6):1119-24. PubMed ID: 12637479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
    Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
    Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
    Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Schrag D; Weiser MR; Goodman KA; Gonen M; Hollywood E; Cercek A; Reidy-Lagunes DL; Gollub MJ; Shia J; Guillem JG; Temple LK; Paty PB; Saltz LB
    J Clin Oncol; 2014 Feb; 32(6):513-8. PubMed ID: 24419115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
    Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
    Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
    Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.
    Cihan Ş; Uncu D; Babacan NA; Özdemir N; Odabaş H; Aksoy S; Öksüzoğlu B; Zengin N
    Asian Pac J Cancer Prev; 2011; 12(4):967-70. PubMed ID: 21790235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
    Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
    Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
    J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.